Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sarepta Therapeutics

- PMLiVE

Prosensa says it could file muscular dystrophy drug this year

Drisapersen still shows promise despite GSK’s decision to terminate collaboration

- PMLiVE

Santhera closer to filing for muscular dystrophy drug

Catena/Raxone slows loss of lung function in late stage trial

- PMLiVE

GSK ends muscular dystrophy deal

Terminates rare disease collaboration with Prosensa after trial disappointment

- PMLiVE

First efficacy data for GSK/Prosensa’s muscular dystrophy candidate positive

Ups ante in race against Sarepta Therapeutics to market first Duchenne muscular dystrophy drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links